BLS - Strong YTD performance

Thursday 19th February 2026

For the third quarter (3Q26) ending 31 December 2025, BLIS Technologies Limited (BLIS) achieved revenue of $3.1m, although being 3% behind the same period last year, the nine months revenue to 31 December 2025 was $10.8m, an increase of $1.5m (17%) on the same period last year.

The EBITDA result for 3Q26 is $0.3m, the same as for the same period last year. For the nine months to 31 December 2025 (YTD), underlying EBITDA is $1.7m after adjusting for the one off supply chain costs noted in previous market updates. Reported EBITDA is $0.8m being an increase of 44% on the same period last year.

“Year to date revenue growth has predominantly come from a $1.4m (21%) increase in B2B revenues, a combination of strong orders from existing ingredient customers, new ingredient customer activity in APAC and growth of private label revenue. Total B2C revenue has grown by $0.3m (9%), with strong performance in the NZ Wholesale channel.” said Scott Johnson, CEO.

“Over the past months, BLIS collaborated closely with Probi AB to revise their joint business plans, aiming to advance the oral probiotics program for both humans and pets. This was a result of the extension of the existing Technology License & Distribution Agreement. This relationship is key to delivering future growth in our B2B business.” said Scott Johnson, CEO.

BLIS’ full year revenue is forecast to be in excess of $14m, with reported EBITDA in the range of $0.8m to $1.1m, subject to completion of the annual financial audit.

Ends

Strong YTD performance

Comments from our readers

No comments yet